Age1 is a longevity-focused venture capital fund investing in companies that target biological aging mechanisms. The thesis is straightforward: aging is the primary risk factor for most major diseases, and addressing it directly is both scientifically sound and commercially viable.
The firm makes early-stage investments in longevity therapeutics and supports founders developing novel approaches t...
Geneva, Switzerland
London, United Kingdom
Seattle, United States
Waltham, United States
San Francisco, United States
Melbourne, Australia